ets-4 Antibody

What is ETS-4 and why is it important in research?

ETS-4 is a transcription factor belonging to the ETS (E26 transformation-specific) family that functions as a sequence-specific DNA binding transcription factor. It plays crucial roles in various biological processes including aging regulation. In C. elegans, ETS-4 has been established as a longevity determinant, with mutations in the ets-4 gene resulting in significant extension of mean life span . The vertebrate ortholog of ETS-4 is SPDEF, suggesting evolutionary conservation of this transcription factor .

When designing experiments with ETS-4 antibodies, it's important to understand that ETS-4 binds to ETS binding sites displaying either a GGAA or GGAT core motif with similar high affinity (KD~10^-9 M) . This DNA-binding specificity is critical for proper interpretation of chromatin immunoprecipitation results.

In which model organisms has ETS-4 been well-characterized?

ETS-4 has been particularly well-studied in Caenorhabditis elegans where it functions as a transcriptional regulator of aging . Studies show that adult worms with ets-4 mutations have significantly extended mean life span.

Additionally, Pt-Ets4 (an ortholog) has been characterized in the spider Parasteatoda tepidariorum where it is expressed during early development, specifically within the central primary thickening and migrating cumulus cells . In this spider model, Pt-Ets4 is needed for cumulus integrity, dorsoventral patterning, and for the activation of developmental genes like Pt-hunchback and Pt-twist .

When validating antibodies across different model organisms, these expression patterns provide useful reference points.

What cellular processes does ETS-4 regulate?

Based on research findings, ETS-4 regulates several key cellular processes:

• Aging and longevity: In C. elegans, ETS-4 functions as a longevity determinant, with mutations leading to extended lifespan .

• Transcriptional regulation: Gene expression profiling identified 70 ETS-4-regulated genes that are enriched for known longevity effectors functioning in lipid transport, lipid metabolism, and innate immunity .

• Developmental processes: In P. tepidariorum, Pt-Ets4 is necessary for cumulus integrity during embryonic development and is involved in axis specification .

• Cell migration: Studies show that Pt-Ets4 plays a role in the migration of cumulus cells during spider embryo development .

When designing experiments to study these processes, antibodies should be validated for the specific cellular context being investigated.

How should I design experiments to validate ETS-4 antibody specificity?

When validating ETS-4 antibodies, a multi-tiered approach is recommended:

• Genetic controls: If available, use ets-4 mutant or knockout models as negative controls. The research shows that ets-4(uz1) and ets-4(ok165) are well-characterized mutations in C. elegans that could serve as ideal negative controls.

• Western blot validation: Look for a single band at the expected molecular weight. Compare wildtype and mutant samples to confirm specificity.

• Immunostaining patterns: In P. tepidariorum, Pt-Ets4 shows specific expression patterns (central cluster of cells at stage 4 and migrating cumulus cells at stage 5) . These distinct localization patterns can help validate antibody specificity.

• Blocking peptide experiments: Pre-incubate antibody with purified ETS-4 protein or peptide to demonstrate signal reduction.

• Multiple antibodies comparison: Use at least two different antibodies targeting distinct epitopes of ETS-4 to corroborate findings.

Remember that the European Monoclonal Antibody Network provides extensive guidance on antibody validation practices that can be applied to ETS-4 antibodies .

What experimental design considerations are important for ChIP experiments with ETS-4 antibodies?

When designing Chromatin Immunoprecipitation (ChIP) experiments for ETS-4:

• Binding site considerations: ETS-4 binds to DNA sequences containing a 5'-GGAA/T-3' core recognition sequence with high affinity (KD~10^-9 M) . Design positive control primers for known binding regions containing these motifs.

• Cross-linking optimization: Since ETS-4 is a transcription factor, optimize formaldehyde cross-linking time (typically 10-15 minutes) to capture DNA-protein interactions effectively.

• Controls:

  • Include IgG control to account for non-specific binding

  • Use ets-4 mutant samples as negative controls

  • Include positive controls targeting regions near known ETS-4-regulated genes (consider the 70 genes identified as ETS-4 targets)

• Sonication parameters: Optimize to achieve DNA fragments of 200-500 bp.

• Sequential ChIP: Consider sequential ChIP if investigating interactions with other transcription factors, particularly GATA factors or DAF-16 (FOXO), which have been shown to share transcriptional targets with ETS-4 .

How can I design experiments to study ETS-4's role in aging pathways?

Based on the research findings, consider these experimental approaches:

• Tissue-specific analysis: Research shows that restoring ETS-4 activity specifically in the intestine, but not neurons, rescues lifespan in ets-4 mutant worms . Design tissue-specific expression systems to study ETS-4 function in relevant tissues.

• Temporal control: Use inducible RNAi or degradation systems to study post-developmental requirements for ETS-4, as research demonstrates it functions post-developmentally to regulate adult lifespan .

• Epistasis experiments: Design genetic interaction studies between ets-4 and other longevity pathways. Research indicates that ets-4 functions in parallel to the insulin/IGF-1 receptor (daf-2) and akt-1/2 kinases, but requires daf-16 to modulate aging .

• Transcriptional profiling: Compare gene expression changes in wild-type versus ets-4 mutants at different ages. The existing data shows 48% overlap between genes altered in different ets-4 mutant alleles, and 24% overlap with aging-regulated genes .

• Include proper controls: Table 2 from the research shows significant overlap between ETS-4-regulated genes and intestine-enriched genes (14%), but minimal overlap with other tissue-specific genes . This information should guide your control selection.

How can I optimize co-immunoprecipitation protocols to identify ETS-4 binding partners?

For optimal co-immunoprecipitation of ETS-4 complexes:

• Buffer optimization: Since ETS-4 is a transcription factor, use nuclear extraction buffers that maintain protein-protein interactions while effectively solubilizing nuclear proteins. Consider testing multiple salt concentrations (150-420 mM NaCl).

• Protein stabilization: Add phosphatase inhibitors and deacetylase inhibitors to preserve post-translational modifications that may mediate interactions.

• Crosslinking consideration: For transient interactions, consider using chemical crosslinkers like DSP (dithiobis(succinimidyl propionate)) that are reversible.

• Sequential immunoprecipitation: For complex interactions, particularly with GATA factors or DAF-16/FOXO which share transcriptional targets with ETS-4 , consider sequential IP approaches.

• Validation strategies:

  • Confirm interactions via reverse co-IP

  • Use transfected tagged constructs to validate interactions

  • Consider proximity ligation assays for in situ validation

Remember that ETS-4 functions in parallel to insulin/IGF-1 signaling components but requires DAF-16 for lifespan effects , suggesting potential physical or functional interactions that could be targeted.

What approaches can differentiate ETS-4 from other ETS family members in immunological assays?

Differentiating between ETS family members requires careful experimental design:

• Epitope selection: Target unique regions outside the conserved ETS domain. The ETS domain is highly conserved among family members and contains the DNA-binding interface that recognizes the 5'-GGAA/T-3' core motif .

• Validation in knockout models: Test antibodies in genetic models lacking ETS-4 but expressing other ETS family members to confirm specificity.

• Pre-absorption controls: Pre-absorb antibodies with recombinant proteins of closely related ETS family members to reduce cross-reactivity.

• Expression pattern analysis: Compare detected patterns with known tissue-specific expression data. Table 2 from the research indicates ETS-4-regulated genes overlap significantly with intestine-enriched genes (14%) but not with other tissue-specific gene sets .

• Size discrimination: On Western blots, carefully compare molecular weights, as different ETS factors may have distinguishable sizes or post-translational modification patterns.

How can I use ETS-4 antibodies to study its role in transcriptional regulation networks?

To investigate ETS-4's role in transcriptional networks:

• ChIP-seq analysis: Perform genome-wide binding site identification for ETS-4, focusing on the 5'-GGAA/T-3' core recognition sequences .

• Integration with expression data: Combine ChIP-seq data with RNA-seq from ets-4 mutants versus wild-type to identify direct transcriptional targets. The research has already identified 70 ETS-4-regulated genes enriched for longevity effectors .

• Co-factor binding studies: Investigate co-localization with known interacting factors, particularly GATA factors and DAF-16/FOXO, which share transcriptional targets with ETS-4 .

• Developmental time course: In developmental studies (like in P. tepidariorum), track ETS-4 binding across developmental stages, particularly during cumulus migration and axis specification .

• Motif analysis: Perform de novo motif discovery on ChIP-seq peaks to identify potential co-factor binding sites adjacent to ETS-4 binding sites.

How do I interpret contradictory results between different ETS-4 antibodies?

When facing contradictory results between different ETS-4 antibodies:

• Epitope mapping: Determine if the antibodies recognize different epitopes. If one antibody targets a region involved in protein-protein interactions, it may show different results in certain contexts.

• Post-translational modifications: Consider whether modifications might affect epitope accessibility. Research shows that transcription factors like ETS-4 are often regulated by phosphorylation or other modifications .

• Isoform specificity: Check if the antibodies recognize different isoforms of ETS-4. Alternative splicing could generate protein variants with different functions.

• Validation hierarchy: Prioritize results from antibodies that have been validated using genetic controls (ets-4 mutants) and multiple techniques.

• Context-dependent effects: Consider whether the contradictions appear only in specific tissues or conditions. Remember that ETS-4 functions differently in different contexts - for example, it's required in the intestine but not neurons for lifespan regulation .

What controls should I include when studying ETS-4's interactions with FOXO/DAF-16 pathway components?

Based on the research showing that ETS-4 requires DAF-16 to modulate aging but functions parallel to insulin/IGF-1 signaling , include these controls:

• Genetic controls:

  • daf-16 mutant samples to verify DAF-16-dependent effects

  • daf-2 mutant samples to assess insulin/IGF-1 pathway independence

  • ets-4; daf-16 double mutants to confirm epistatic relationships

  • ets-4; daf-2 double mutants to confirm parallel pathway function

• Expression controls:

  • Monitor both ETS-4 and DAF-16 expression levels in experimental conditions

  • Verify that manipulating one factor doesn't alter expression of the other

• Target gene analysis:

  • Include known DAF-16 target genes (20% overlap with ETS-4 regulated genes)

  • Include known ETS-4-specific targets not regulated by DAF-16

  • Include genes regulated by both factors

• Localization controls:

  • Track nuclear localization of both factors under various conditions

  • Assess whether manipulating one factor affects localization of the other

How can I resolve high background issues in immunofluorescence with ETS-4 antibodies?

To reduce background in ETS-4 immunofluorescence experiments:

• Fixation optimization: Test different fixation methods (paraformaldehyde, methanol, or combinations) as transcription factors may require specific conditions to preserve epitopes while reducing non-specific binding.

• Blocking enhancement: Extend blocking time (2-4 hours) and test different blocking agents (BSA, normal serum, casein). Consider adding 0.1-0.3% Triton X-100 to improve antibody penetration.

• Antibody concentration titration: Perform a dilution series of primary antibody to identify optimal concentration that maximizes signal-to-noise ratio.

• Signal amplification alternatives: Consider tyramide signal amplification (TSA) which can allow use of more dilute primary antibody while maintaining signal strength.

• Reference expression patterns: In P. tepidariorum, Pt-Ets4 shows specific expression patterns (central primary thickening at stage 4 and migrating cumulus cells at stage 5) . Use these distinctive patterns as references when optimizing protocols.

How can ETS-4 antibodies be used to investigate its role in aging across different model organisms?

Building on the findings that ETS-4 regulates lifespan in C. elegans :

• Cross-species validation: Test commercially available antibodies against ETS-4 orthologs (like SPDEF in vertebrates) using conserved epitopes.

• Tissue-specific aging biomarkers: Develop immunohistochemistry protocols to track ETS-4 expression changes during aging in different tissues, focusing first on intestinal tissue where ETS-4 has known function in lifespan regulation .

• Comparative approaches: Analyze ETS-4 expression and localization across species with different lifespans to identify conserved regulatory mechanisms.

• Integration with aging pathways: Design multiplexed immunofluorescence protocols to simultaneously detect ETS-4 with other longevity regulators like DAF-16/FOXO factors.

• Post-translational modification mapping: Develop antibodies specific to modified forms of ETS-4 to track age-related changes in its activation state.

What are the best experimental approaches to study ETS-4's dual roles in development and aging?

To investigate the dual functionality of ETS-4:

• Temporal expression analysis: Use antibodies to track ETS-4 expression across developmental stages and aging timepoints, similar to the developmental tracking done in P. tepidariorum .

• Conditional systems: Employ temperature-sensitive or drug-inducible systems to manipulate ETS-4 function at specific developmental stages or ages.

• Target gene comparison: Compare the 70 ETS-4-regulated genes identified in aging contexts with developmental targets like twist and hunchback in P. tepidariorum to identify shared regulatory mechanisms.

• ChIP-seq comparison: Compare ETS-4 binding profiles between embryonic and aged tissues to identify context-dependent binding patterns.

• Functional domain analysis: Use structure-function analysis with domain-specific antibodies to determine if different protein domains mediate developmental versus aging functions.